Curis, Inc. (NASDAQ:CRIS)

CAPS Rating: 4 out of 5

A drug discovery and development company that is seeking to leverage its innovative biological signaling pathway drug technologies to create new medicines primarily in the field of cancer.

Recs

0
Player Avatar CarlosDK (< 20) Submitted: 12/5/2012 5:22:33 PM : Outperform Start Price: $3.14 CRIS Score: +6.05

Pattern length

Featured Broker Partners


Advertisement